Therapeutics and The Netherlands Organization for Applied Scientific Research
(TNO) signed an agreement to further develop Amarna’s viral gene delivery
. TNO will develop novel methods for the manufacture, formulation, and testing of the SV40-based system.
Amarna says that the partnership will enable it to start clinical trials with one of its lead therapeutics in 2010. The collaboration will be funded in part by a co-financing initiative aimed at developing innovative technologies. Amarna is initially exploiting SVac for the development of a vaccine against multiple sclerosis followed by a breast cancer vaccine.
Amarna claims that the SVac platform is nonimmunogenic in humans, making it the only vector system suitable for treating immunity-associated diseases by reprogramming immune responses and for genetic disorders by preventing immune responses to introduced therapeutic genes. The vector is also safe, stable, and amenable to large-scale production, as the proprietary SuperVero cells used to replicate the SV40 particles can be grown in suspension culture systems using commercial human and animal protein-free media, the company adds.